A Phase 2, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Efficacy of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia (CAH)
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2018
At a glance
- Drugs SPR-001 (Primary)
- Indications Congenital adrenal hyperplasia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Spruce Biosciences
- 10 Sep 2018 Planned End Date changed from 1 Jul 2018 to 31 Jan 2019.
- 10 Sep 2018 Planned primary completion date changed from 1 Jun 2018 to 30 Nov 2018.
- 31 Aug 2018 Biomarkers information updated